Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

Molecular Cancer Therapeutics
Salvatore LopezAlessandro D Santin

Abstract

HER2/neu gene amplification and PIK3CA driver mutations are common in uterine serous carcinoma (USC) and may represent ideal therapeutic targets against this aggressive variant of endometrial cancer. We examined the sensitivity to neratinib, taselisib, and the combination of the two compounds in in vitro and in vivo experiments using PIK3CA-mutated and PIK3CA wild-type HER2/neu-amplified USC cell lines. Cell viability and cell-cycle distribution were assessed using flow-cytometry assays. Downstream signaling was assessed by immunoblotting. Preclinical efficacy of single versus dual inhibition was evaluated in vivo using two USC xenografts. We found both single-agent neratinib and taselisib to be active but only transiently effective in controlling the in vivo growth of USC xenografts harboring HER2/neu gene amplification with or without oncogenic PIK3CA mutations. In contrast, the combination of the two inhibitors caused a stronger and long-lasting growth inhibition in both USC xenografts when compared with single-agent therapy. Combined targeting of HER2 and PIK3CA was associated with a significant and dose-dependent increase in the percentage of cells in the G0-G1 phase of the cell cycle and a dose-dependent decline in the ph...Continue Reading

References

Mar 1, 1982·The American Journal of Surgical Pathology·M HendricksonR Kempson
Sep 1, 1994·Gynecologic Oncology·B A GoffB E Greer
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Nov 3, 2004·Cancer Research·Ian G CampbellWayne A Phillips
Jan 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·Sohye KangPeter K Vogt
Oct 21, 2005·The New England Journal of Medicine·Harold J Burstein
Jul 19, 2006·Nature Reviews. Genetics·Jeffrey A EngelmanLewis C Cantley
Jan 2, 2008·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jaclyn LoPiccoloPhillip A Dennis
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey A Engelman, Pasi A Jänne
May 22, 2008·Archiv der Pharmazie·Allan Wissner, Tarek S Mansour
Mar 6, 2009·Proceedings of the National Academy of Sciences of the United States of America·H B SalvesenR Beroukhim
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y KataokaH Minami
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Dec 3, 2009·Current Opinion in Obstetrics & Gynecology·Amanda Nickles FaderPaola A Gehrig
Apr 14, 2010·Molecular Cancer·J Rafael SierraSilvia Giordano
Apr 22, 2011·Clinical Obstetrics and Gynecology·Kathleen N Moore, Amanda Nickles Fader
Jun 21, 2011·Journal of Biomedicine & Biotechnology·Takayuki KosakaHiroyuki Kuwano
Mar 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Celina García-GarcíaMaurizio Scaltriti
Aug 28, 2012·Journal of the National Cancer Institute·Elisabetta KuhnIe-Ming Shih
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Jan 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Siming ZhaoAlessandro D Santin
Mar 27, 2013·Molecular Diagnosis & Therapy·Diana P EnglishAlessandro D Santin
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
May 11, 2013·International Journal of Clinical Oncology·Yiting GengYongmei Yin
May 15, 2013·Chinese Journal of Cancer·Jing Tan, Qiang Yu
Jun 15, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Natalia BuzaPei Hui
Jan 10, 2014·Cancer Discovery
Feb 15, 2014·TheScientificWorldJournal·Athanasia Pavlidou, Nikos F Vlahos
Mar 1, 2014·Archives of Pathology & Laboratory Medicine·Natalia BuzaAlessandro D Santin
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Neil A O'BrienDennis J Slamon
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 17, 2015·Future Oncology·Juan Martin-Liberal, James Larkin

❮ Previous
Next ❯

Citations

Oct 4, 2015·Gynecologic Oncology·Amy Bregar, Whitfield Growdon
Dec 8, 2017·Gynecologic Oncology Research and Practice·Vicky MakkerDavid Scott Miller
Dec 14, 2019·Current Opinion in Obstetrics & Gynecology·Britt K EricksonAmanda N Fader
Mar 19, 2020·Cancers·Li ZhangSamuel C Mok
Sep 9, 2017·Drugs·Emma D Deeks
Jun 20, 2019·Frontiers in Oncology·Michiel Remmerie, Veerle Janssens
Aug 15, 2018·International Journal of Molecular Sciences·Michiel Remmerie, Veerle Janssens
Jun 27, 2018·Journal of Hematology & Oncology·Sophie CousinAntoine Italiano
Sep 25, 2016·Proceedings of the National Academy of Sciences of the United States of America·Yang DengW Mark Saltzman
Jul 7, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gulden MenderesAlessandro D Santin
Jan 12, 2019·Gynecologic Oncology·Elena BonazzoliAlessandro D Santin
May 4, 2021·Gynecologic Oncology·Giorgio BoganiBradley J Monk

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.